Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3986021
Max Phase: Preclinical
Molecular Formula: C51H57ClN6O7S
Molecular Weight: 933.57
Molecule Type: Small molecule
Associated Items:
ID: ALA3986021
Max Phase: Preclinical
Molecular Formula: C51H57ClN6O7S
Molecular Weight: 933.57
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC56CC7CC(CC(O)(C7)C5)C6)c([N+](=O)[O-])c4)c(Oc4ccc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Standard InChI: InChI=1S/C51H57ClN6O7S/c1-49(2)15-13-37(43(29-49)35-3-5-38(52)6-4-35)30-56-17-19-57(20-18-56)39-7-10-42(47(23-39)65-40-8-11-44-36(22-40)14-16-53-44)48(59)55-66(63,64)41-9-12-45(46(24-41)58(61)62)54-32-50-25-33-21-34(26-50)28-51(60,27-33)31-50/h3-12,14,16,22-24,33-34,53-54,60H,13,15,17-21,25-32H2,1-2H3,(H,55,59)
Standard InChI Key: FRVNNLJWAMTMHE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 933.57 | Molecular Weight (Monoisotopic): 932.3698 | AlogP: 10.17 | #Rotatable Bonds: 13 |
Polar Surface Area: 170.14 | Molecular Species: ACID | HBA: 10 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.18 | CX Basic pKa: 7.96 | CX LogP: 8.30 | CX LogD: 8.42 |
Aromatic Rings: 5 | Heavy Atoms: 66 | QED Weighted: 0.07 | Np Likeness Score: -0.85 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
2. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):